Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
Share Fallers
Why Ardent Leisure, BWX, Mayne Pharma, & New Hope are sinking lower
Share Market News
ASX 200 lunch update: ANZ & Sydney Airport up, Mayne Pharma sinks
Share Market News
Mayne Pharma share price sinks lower on $17.5 million half year loss
Share Market News
5 things to watch on the ASX 200 on Friday
52-Week Lows
Why Mayne Pharma and these ASX shares just hit multi-year lows
52-Week Lows
Are Mayne Pharma shares in the bargain bin?
Share Market News
Why these ASX 200 shares are falling today
Share Fallers
Why G8 Education and these ASX 200 shares have crashed lower in recent months
Healthcare Shares
Can these 2 ASX healthcare shares recover in 2020?
Share Fallers
These were the worst performing ASX 200 shares in 2019
Share Fallers
Why the Mayne Pharma share price is down over 50% in 12 months
Share Market News
ALL ORDINARIES finishes lower Tuesday: 8 ASX shares you missed
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
